MCHC Offers Monoclonal Antibody Therapy for COVID
MCHC News Release
Molokai Community Health Center (MCHC) in partnership with the U.S. Department of Health and Human Services (HHS) is pleased to announce access to monoclonal antibody therapy (mAb), Regeneron, at its facility. This one-time therapy is highly effective in preventing severe disease and hospitalization caused by COVID-19.
In high-risk COVID-19 patients, this medication can be given up to 10 days after the first onset of symptoms or positive test. The earlier in infection Regeneron is given, the more effective it is likely to be. This medication is also approved to be used by high-risk patients who have not tested positive for COVID-19 as soon as possible after a known COVID exposure.…